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We appreciate Maniscalco and Motta’s comments on our
recently published article ‘‘Fusion of the 1H NMR data of
serum, urine and exhaled breath condensate in order to
discriminate chronic obstructive pulmonary disease and
obstructive sleep apnea syndrome’’ (Zabek et al. 2015) and
we are grateful for the opportunity to clarify a number of
points from our work. We are glad that the authors
appreciated our data analysis and interpretation.
Fusion of metabolomic data is an outstanding tool for a
comprehensive description of patient’s phenotype that
combines metabolic profiles acquired in different domains.
Such an integrative approach is highly valued in the so-
called ‘breathomics’ (Smolinska et al. 2014) for a better
understanding of the complex respiratory diseases and
discovering their biomarkers (Sterk et al. 2013). Our work
was an attempt to provide a novel comprehensive
description of metabolic phenotype and to test its utility in
order to discriminate between two closely related respira-
tory pathological conditions.
We performed a very careful selection of patients and
those with an overlap syndrome who suffered from both
COPD and OSAS (a total of 21 individuals) were not
considered in our study. A further reduction in the number
of patients was obtained by eliminating patients who did
not deliver samples of all three biofluids for analysis.
Therefore, even though a total of 85 serum, 91 urine and 82
EBC samples were collected, only 46 individuals (18
patients with COPD and 28 patients with the OSA syn-
drome) were finally included in the study. The selection of
samples is in agreement with the assumption that changes
in the level of a metabolite or a combination of metabolites
present in different biofluids may be characteristic for a
disease at all stages of its progression, regardless of the
degree of the severity of the disease, obesity or smoking
habits of the patients. Therefore, in our opinion, the
hypothesis suggested by Maniscalco and Motta that the
‘lower specificity’ of the models combining EBC and other
biofluids might be related to the severity of the disease
would require further verification using specifically
designed data. In order to assess the effect of the severity of
a disease, obesity or smoking habits on the metabolic
profiles, analysis of data in which a strict categorization of
COPD and OSAS patients according to their clinical pro-
files is required. Unfortunately, it was not possible to
present an analysis of such designed data in our article due
to the small number of samples. Stratification of patients
based on spirometric results was out of the scope of this
study. A comparison of our results and the results presented
in the recent publication authored by Maniscalco and Motta
(Paris et al. 2015) is hindered due to the differences in
normalization methods that were used. We are currently
developing a more comprehensive clinical trial that we
hope will provide a clearer answer to the questions that
have been raised.
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It is our conviction that our work will be a useful con-
tribution to the field of metabolomics and will help to
better understand the metabolic mechanisms of respiratory
pathologies.
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